These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215 [Abstract] [Full Text] [Related]
6. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, Blank SV. Gynecol Oncol; 2015 Nov; 139(2):211-5. PubMed ID: 26296696 [Abstract] [Full Text] [Related]
7. Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Culver JO, Brinkerhoff CD, Clague J, Yang K, Singh KE, Sand SR, Weitzel JN. Clin Genet; 2013 Nov; 84(5):464-72. PubMed ID: 23323793 [Abstract] [Full Text] [Related]
8. Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing. Mooney R, Espinel W, Elrick A, Kehoe K, Kohlmann W, Kaphingst KA. J Genet Couns; 2022 Apr; 31(2):470-478. PubMed ID: 34570943 [Abstract] [Full Text] [Related]
9. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, Horick N, Yang S, Shannon KM, Tung N, Ford JM, Lincoln SE, Ellisen LW. JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [Abstract] [Full Text] [Related]
13. Psychological distress related to BRCA testing in ovarian cancer patients. Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A. Fam Cancer; 2015 Dec; 14(4):495-504. PubMed ID: 25980896 [Abstract] [Full Text] [Related]
14. Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study. Adam F, Fluri M, Scherz A, Rabaglio M. BMC Med Genomics; 2023 Jan 16; 16(1):7. PubMed ID: 36647026 [Abstract] [Full Text] [Related]
16. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention. McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP. Am J Med Genet A; 2004 Oct 15; 130A(3):221-7. PubMed ID: 15378542 [Abstract] [Full Text] [Related]
18. How to facilitate psychosocial adjustment in women tested for hereditary breast or ovarian cancer susceptibility? Insights from network analysis. Brédart A, Dick J, Cano A, Robieux L, De Pauw A, Schmutzler R, Stoppa-Lyonnet D, Dolbeault S, Kop JL. Psychooncology; 2020 Mar 15; 29(3):550-556. PubMed ID: 31823434 [Abstract] [Full Text] [Related]
19. Psychological distress following multi-gene panel testing for hereditary breast and ovarian cancer risk. Carlsson L, Bedard PL, Kim RH, Metcalfe K. J Genet Couns; 2024 Jul 23. PubMed ID: 39044246 [Abstract] [Full Text] [Related]